摘要
炎症性肠病（IBD）是病因不明的慢性肠道炎症性疾病，可能与环境、遗传和免疫等因素有关。IBD个体化或精准诊疗是目前IBD临床管理发展的新方向。生物标志物的检测在IBD的诊疗和临床管理中显得十分重要，除了传统生物标志物外，基于遗传学、miRNA及代谢组学等新型标志物在IBD的诊断和鉴别诊断；疾病活动性、严重程度及并发症的判定；治疗方案选择和治疗效果的预测等方面的有良好的应用前景，并将有助于临床IBD患者实现个体化管理。
Inflammatory bowel disease is chronic intestinal inflammatory disease with unknown etiology, which may be associated with environmental, genetic and immune factors. The personalized or accurate diagnosis and treatment are a new development trend for IBD clinical management. The detection of biomarkers is very important in the diagnosis, treatment and clinical management of IBD. In addition to the traditional biomarkers, the emerging new markers based on genetics, epigenetics, microbial and metabolomics have also shown better future applications in several areas, such as the applications of biomarkers in diagnosis and differential diagnosis of IBD. The determination of disease activity, severity and complications. The selection for treatments in IBD and prediction of therapeutic effects. These biomarkers will also contribute to personalized clinical management of IBD.（Chin J Lab Med, 2018, 41： 703-707）
作者
卢洁
谢鑫友
张钧
Lu Jie;Xie Xinyou;Zhang Jun(Clinical Laboratory,Sir Run Run Shaw Hospital,School of Medicine,Zhefiang University,Hangzhou 310016,China)
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2018年第10期703-707,共5页
Chinese Journal of Laboratory Medicine
关键词
炎性肠疾病
生物标记
精准医学
Inflammatory bowel diseases
Biomarkers
Precision medicine
